Trial ID or NCT#

NCT03733210

Status

not recruiting iconNOT RECRUITING

Purpose

This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans make detailed, computerized pictures of areas inside the body where the drug is used. Giving panitumumab IRDye800 and 89Zr panitumumab to patients with head and neck cancer may help doctors find metastatic lymph nodes better than current methods [positron emission tomography (PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations].

Official Title

Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Eben Rosenthal
Eben Rosenthal
Otolaryngologist, Head and neck surgeon
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiology (Molecular Imaging Program at Stanford)

Contact us to find out if this trial is right for you.

CONTACT

Alexander Ayon Valencia
(650) 498-5185